187 related articles for article (PubMed ID: 34546644)
1. Disease progression and mortality with untreated HIV infection: evidence synthesis of HIV seroconverter cohorts, antiretroviral treatment clinical cohorts and population-based survey data.
Glaubius R; Kothegal N; Birhanu S; Jonnalagadda S; Mahiane SG; Johnson LF; Brown T; Stover J; Mangal TD; Pantazis N; Eaton JW
J Int AIDS Soc; 2021 Sep; 24 Suppl 5(Suppl 5):e25784. PubMed ID: 34546644
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.
Haas AD; Radin E; Hakim AJ; Jahn A; Philip NM; Jonnalagadda S; Saito S; Low A; Patel H; Schwitters AM; Rogers JH; Frederix K; Kim E; Bello G; Williams DB; Parekh B; Sachathep K; Barradas DT; Kalua T; Birhanu S; Musuka G; Mugurungi O; Tippett Barr BA; Sleeman K; Mulenga LB; Thin K; Ao TT; Brown K; Voetsch AC; Justman JE
J Int AIDS Soc; 2020 Nov; 23(11):e25631. PubMed ID: 33225559
[TBL] [Abstract][Full Text] [Related]
3. Assessing linear CD4 decline quantifying diagnosis delay after HIV seroconversion: assessing the linearity assumption of CD4 decline.
Robertson MM; Braunstein SL; Hoover DR; Li S; Nash D
Ann Epidemiol; 2020 Dec; 52():1-6. PubMed ID: 32791198
[TBL] [Abstract][Full Text] [Related]
4. CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa.
Lewden C; Gabillard D; Minga A; Ekouévi DK; Avit D; Konate I; Amani-Bossé C; Messou E; Coffie P; Ouedraogo A; Laurent C; Anglaret X;
J Acquir Immune Defic Syndr; 2012 Feb; 59(2):213-9. PubMed ID: 22027874
[TBL] [Abstract][Full Text] [Related]
5. Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection.
Mangal TD;
AIDS; 2017 May; 31(8):1073-1082. PubMed ID: 28301424
[TBL] [Abstract][Full Text] [Related]
6. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.
Pantazis N; Morrison C; Amornkul PN; Lewden C; Salata RA; Minga A; Chipato T; Jaffe H; Lakhi S; Karita E; Porter K; Meyer L; Touloumi G;
PLoS One; 2012; 7(3):e32369. PubMed ID: 22412867
[TBL] [Abstract][Full Text] [Related]
7. Impact of age on CD4 recovery and viral suppression over time among adults living with HIV who initiated antiretroviral therapy in the African Cohort Study.
Bahemana E; Esber A; Dear N; Ganesan K; Parikh A; Reed D; Maganga L; Khamadi S; Mizinduko M; Lwilla A; Mkondoo D; Mwaisanga G; Somi N; Owouth J; Maswai J; Kiweewa F; Iroezindu M; Ake JA; Crowell TA; Valcour VG; Polyak CS;
AIDS Res Ther; 2020 Nov; 17(1):66. PubMed ID: 33183355
[TBL] [Abstract][Full Text] [Related]
8. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis.
Siedner MJ; Ng CK; Bassett IV; Katz IT; Bangsberg DR; Tsai AC
Clin Infect Dis; 2015 Apr; 60(7):1120-7. PubMed ID: 25516189
[TBL] [Abstract][Full Text] [Related]
9. Updates to the Spectrum/AIM model for the UNAIDS 2020 HIV estimates.
Stover J; Glaubius R; Kassanjee R; Dugdale CM
J Int AIDS Soc; 2021 Sep; 24 Suppl 5(Suppl 5):e25778. PubMed ID: 34546648
[TBL] [Abstract][Full Text] [Related]
10. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.
Cornell M; Schomaker M; Garone DB; Giddy J; Hoffmann CJ; Lessells R; Maskew M; Prozesky H; Wood R; Johnson LF; Egger M; Boulle A; Myer L;
PLoS Med; 2012; 9(9):e1001304. PubMed ID: 22973181
[TBL] [Abstract][Full Text] [Related]
11. Markov modelling of viral load adjusting for CD4 orthogonal variable and multivariate conditional autoregressive mapping of the HIV immunological outcomes among ART patients in Zimbabwe.
Matsena Zingoni Z; Chirwa TF; Todd J; Musenge E
Theor Biol Med Model; 2021 Aug; 18(1):16. PubMed ID: 34419087
[TBL] [Abstract][Full Text] [Related]
12. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
Bwire R; Nagelkerke NJ; Borgdorff MW
Trop Med Int Health; 2006 Oct; 11(10):1567-75. PubMed ID: 17002731
[TBL] [Abstract][Full Text] [Related]
13. CD4 Cell Count: Declining Value for Antiretroviral Therapy Eligibility.
Ying R; Granich RM; Gupta S; Williams BG
Clin Infect Dis; 2016 Apr; 62(8):1022-8. PubMed ID: 26826372
[TBL] [Abstract][Full Text] [Related]
14. Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM?
Gras L; Geskus RB; Jurriaans S; Bakker M; van Sighem A; Bezemer D; Fraser C; Prins JM; Berkhout B; de Wolf F;
PLoS One; 2013; 8(5):e64437. PubMed ID: 23724048
[TBL] [Abstract][Full Text] [Related]
15. Mortality estimates by age and sex among persons living with HIV after ART initiation in Zambia using electronic medical records supplemented with tracing a sample of lost patients: A cohort study.
Kerkhoff AD; Sikombe K; Eshun-Wilson I; Sikazwe I; Glidden DV; Pry JM; Somwe P; Beres LK; Simbeza S; Mwamba C; Bukankala C; Hantuba C; Moore CB; Holmes CB; Padian N; Geng EH
PLoS Med; 2020 May; 17(5):e1003107. PubMed ID: 32401797
[TBL] [Abstract][Full Text] [Related]
16. High CD4 counts associated with better economic outcomes for HIV-positive adults and their HIV-negative household members in the SEARCH Trial.
Jakubowski A; Snyman K; Kwarisiima D; Sang N; Burger R; Balzer L; Clark T; Chamie G; Shade S; Cohen C; Bukusi E; Charlebois E; Kamya M; Petersen M; Havlir D; Thirumurthy H
PLoS One; 2018; 13(6):e0198912. PubMed ID: 29944678
[TBL] [Abstract][Full Text] [Related]
17. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.
Lawn SD; Myer L; Bekker LG; Wood R
BMC Infect Dis; 2006 Mar; 6():59. PubMed ID: 16551345
[TBL] [Abstract][Full Text] [Related]
18. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies.
Johnson LF; Mossong J; Dorrington RE; Schomaker M; Hoffmann CJ; Keiser O; Fox MP; Wood R; Prozesky H; Giddy J; Garone DB; Cornell M; Egger M; Boulle A;
PLoS Med; 2013; 10(4):e1001418. PubMed ID: 23585736
[TBL] [Abstract][Full Text] [Related]
19. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.
Anglaret X; Scott CA; Walensky RP; Ouattara E; Losina E; Moh R; Becker JE; Uhler L; Danel C; Messou E; Eholié S; Freedberg KA
Antivir Ther; 2013; 18(1):45-55. PubMed ID: 22809695
[TBL] [Abstract][Full Text] [Related]
20. Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis.
Kelly H; Chikandiwa A; Alemany Vilches L; Palefsky JM; de Sanjose S; Mayaud P
Lancet HIV; 2020 Apr; 7(4):e262-e278. PubMed ID: 32109408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
